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ABSTRACT
Although both chemotherapy and hyperthermia therapy have their inherent advantages,
the non-specific targeting of chemotherapy and ineffectiveness of hyperthermia therapy
alone suggests a better method can be developed. To overcome this problem, the
combined treatment of chemotherapeutic agents with plasmonic photothermal therapy
(PPTT) is proposed. This is the first study to investigate the efficacy of combined
chemotherapy and PPTT using monocytes as delivery vehicles for gold nanoshells. The
results of this investigation shows that PPTT combined with cisplatin resulted in some
degree of synergism while additive effects were observed for concurrent treatments of
PPTT and doxorubicin and PPTT and bleomycin.
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CHAPTER 1

INTRODUCTION
1.1 Hypopharyngeal Squamous Cell Carcinoma
Hypopharyngeal cancers are relatively uncommon: each year approximately
2,500 new cases are diagnosed in the U.S (American Cancer Society, 2014). These
cancers can be divided into upper hypopharyngeal and lower hypopharyngeal cancers.
Upper hypopharyngeal cancers are more closely linked with heavy drinking and smoking,
in comparison to the lower hypopharyngeal, or the postcricoid, cancers which are more
frequently associated with nutritional deficiencies. Currently, the majority of
hypopharyngeal cancers are mucosal squamous cell carcinomas (SCC). Current treatment
for many cancers such as brain, hypopharyngeal squamous cell carcinomas and breast
include surgical resection of the tumor followed by various concurrent or subsequent
treatments such as chemo and/or radiotherapy. The goal of subsequent treatments is to
eliminate the malignant cells residing in the margin surrounding the resection cavity
thereby reducing or eliminating recurrence. Unfortunately, in many cases, none of the
standard treatment regimens have proven to be successful suggesting that alternative
therapeutic approaches are required.
Almost all cancers in the hypopharynx originate from thin, flat cells of squamous
cells located in the innermost layer of the epidermis (Fig. 1) Cancers originating in this
layer are called squamous cell carcinoma or squamous cell cancer. Most squamous cell
cancers begin as a pre-cancerous condition of dysplasia, and when seen under a
microscope, the cells look abnormal but not yet cancerous. Often this condition resolves
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on its own without any treatments, especially if the underlying cause is addressed. Most
patients with dysplasia do not have any symptoms unless it is on the vocal cord. In some
cases, the dysplasia will progress to carcinoma in situ (CIS). In this condition, the cancer
cells are seen in the epithelial lining of the hypopharynx, but have not grown into deep
layers or spread to other parts of the body. Carcinoma in situ is the earliest form of cancer
and can be cured at this stage. If carcinoma in situ is not treated, it can develop into an
invasive squamous cell cancer which can destroy nearby tissues and spread to other parts
of the body.

Figure 1 Right hypopharyngeal wall squamous cell carcinoma extending from the tonsil down to the pyriform sinus
(Ghorayeb, 2014)

Clinically, hypopharyngeal cancers have the tendency to be aggressive: they are
characterized by diffuse local and distant spread and, as such, they tend to metastasize in
their early stages. In a large study of patients with SCC of the pharynx and hypopharynx,
2

87% of patients with pyriform sinus SCC were found to have stage III or stage IV disease;
82% of patients with SCC of the posterior pharyngeal wall were found to have stage III
or stage IV disease (American Cancer Society, 2014).
In general, hypopharyngeal cancer treatments are controversial. To some extent,
this is attributed to its low incidence and the inherent difficulty in conducting adequately
powered, prospective, randomized clinical studies (Trinidad et al., 2014). For this reason,
it is difficult to identify the ideal therapy for a specific site or stage for this type of cancer.
Primary treatment consists of surgery and radiation therapy however, in recent years,
chemotherapy has been added for some select advanced hypopharyngeal cancers.
The overall poor prognosis of hypopharyngeal squamous cell carcinomas is due to
a number of factors including presentation at a late stage, multisite involvement within
the hypopharynx, unrestricted soft-tissue tumor growth, an extensive regional lymphatic
network allowing metastases development, and restricted surgical options for complete
resection. Local and regional recurrences are the most common causes of treatment
failure. Following a definitive treatment, most failures occur within the first 2 years. In
addition to the risk of delayed regional metastases, the risk of developing a second
primary tumor in patients with tumors of the upper aerodigestive tract has been estimated
to be 4 to 7% per year (American Cancer Society, 2014). Surveillance of patients with
hypopharyngeal cancer should be lifelong because of these risks. Five year survival rates
for hypopharyngeal cancer are summarized in Table 1
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Hypopharynx Cancer Stage

5-year relative survival rate

I

53%

II

39%

III

36%

IV

24%

Table 1 Survival rates of hypopharynx cancer by stage (AJCC Cancer Staging Manual, Seventh Edition)

1.2 Human Hypopharyngeal FaDu (HTB-43) Head and Neck Cell Monolayer
An epithelial cell line was established from a hypopharyngeal squamous cell
carcinoma during the course of a study on the adenovirus-induced T-antigens in human
oral and pharyngeal tumor tissues. This cell line was named FaDu, in honor of the patient
from which the tissue was removed. This is a squamous cell carcinoma of the
laryngopharynx (Grade II) which has been cultured since 1968. After the initial thirty
serial subpassages, this cell line has retained the epithelial morphology and orderly
growth as a monolayer sheet.
From the first tissue culture (Fig. 2), the polygonal-shaped and compactly packed
epithelial cells migrated out of the explant three days after the beginning of the culture.
Furthermore, many fibroblastic-type cells were on the outward growth from the explant,
and many mitotic cells were observed in the peripheral regions of the epithelial
outgrowth. The monolayer sheet of cells was obtained from the cellular outgrowths
similar to the epithelial elements observed in the primary cultures (Fig. 3). Due to the
early stage difficulties of cellular repopulating in the subpassage cultures, complete
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isolation of individual cells from the cell sheet was not achieved until the thirtieth
passage level.

Figure 2 First passage explant on collagen-coated glass tube 8 days after transfer (Rangan. 1972)

Morphologically, the cells were and continue to be epithelial in nature. In phase
contrast microscopy images, dense granular material in the cytoplasm and around the
nucleus is seen in the cells at all passage levels (Rangan. 1972). In the monolayer, multilayered focal regions of the cells are frequently observed. The average population
doubling time of the cell line at the 16th passage level was found to be approximately 50
hours (Fig. 3). With regards to the malignant properties of the cell line, the original study
by Rangan (1972) showed two of the four ten-day-old chick-chorioallantoic membranes
seeded with cell suspension developing single discrete nodular growth. From histological
5

studies, the nodules were found to contain identical cellular elements to those in the
tissue culture.

Figure3 Growth curve of the cell line at the 16th passage level (Rangan. 1972)

In the preliminary virus infection studies, the cell line was found to be susceptible
to some viruses containing either RNA or DNA. In particular, the parainfluenza viruses,
types 2 and 3 were found to infect the cells. Additionally, cultures infected with
adenoviruses, type 3 and 12, revealed typical cytopathic changes and numerous
intranuclear aggregates of virus particles in thick sections of the cell (Rangan, 1972),
however, the cells were not susceptible to SV40 virus.

1.3 P388D-1 Murine Lymphocytic Monocytes
Monocytes are precursor cells that differentiate into macrophages once they have
migrated from the circulation into the tissue where they reside (Owen et al., 2004;
Murdoch and Lewis, 2005). In general, macrophages are categorized as white blood cells
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originating from myeloid progenitor cells of the bone marrow and they are the first to
mediate host immune responses against foreign objects. In addition to their role in
phagocytosis of invading pathogens, macrophages also release several growth factors
such as cytokines and interleukins (e.g. transforming growth factor-β (TGF-β) and
platelet-derived growth factor), and they are involved in a number of other inflammatory
responses as well as in the repair of damaged tissues (Metz et al., 2004; Hsiao et al.,
2008).
Macrophages play a central regulatory and effector role in the immune response
of the body against neoplasia (Fidler et al., 1988). They are transformed into an activated
state from the resting state in response to a variety of foreign stimuli like bacteria, viruses,
and tumors. These activated macrophages release TNF, IL-1, nitric oxide, lysozymes, and
other cytokines which can kill tumor cells and activate the host immune response (Adams,
1992).
It has been demonstrated that certain antineoplastic drugs confer a dual
functionality to macrophages. i.e., these drugs act as both tumoricidal agents and
immunopotentiators; a well-documented example of this phenomenon is cisplatin. It has
been reported that murine macrophages treated with cisplatin showed enhanced
capacity to lyse tumor cells in vitro and also resulted in increased production of
IL-1, TNF, reactive oxygen intermediates, reactive nitrogen intermediates, lysozyme and
arginase (Singh et al., 1991; Alaparthy et al., 1991). Furthermore, P388D-1 cells treated
with

different

concentrations

of

cytosine

arabbinoside,

vincristine

sulphate,

cyclophosphamide, mitomycin C, and hydroxyl urea showed increased IL-1 activity, and
enhanced cytotoxicity (Pai et al., 1997).

7

In addition to neoplastic cells and blood vessels, tumors are also composed of
leukocytes, specifically macrophages. These macrophages are known as tumor-associated
macrophages (TAMs) which are monocytes that are recruited into the tumor and
comprise up to 50% of the tumor’s cellular mass (Murdoch and Lewis, 2005; Knowles
and Harris, 2007). In the case of squamous cell carcinomas, the tumor-infiltrating cells
consist mainly of T lymphocytes, monocytes and macrophages. For a tumor to be able to
utilize macrophages for their benefit, the macrophages must first be recruited, and to
achieve this, tumors induce a chemo-attractive gradient by secreting a number of factors,
the most important of which are chemokines (Choi et al., 2007).
Macrophages have become a very attractive carrier for the delivery of therapeutic
agents due to their inherent ability to migrate and aggregate within and around the tumor,
especially in hypoxic regions. A key benefit of using a cell-based delivery system is the
increase in the nanoparticle’s systemic half-life because macrophages act as protectors
against reticulo-endothelial elimination. From a clinical perspective, the basic procedure
for such a strategy involves isolation of macrophages from a given patient followed by
macrophage loading of the agent of interest (e.g. nanoparticles) which are then injected
into the patient (Owen et al., 2004; Murdoch and Lewis, 2005; Knowles and Harris,
2007).
Cell-based vectorization is one method that can target and maintain an elevated
concentration of nanoparticles at the tumor site and prevent their spread into normal
tissue (Madsen et al., 2012a). Employing macrophages, in conjunction with nanoparticle
delivery for plasmonic photothermal therapy (PPTT) has interesting potential for cancer
treatment since they are attracted to hypoxic and necrotic regions within tumors.
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Macrophages have been shown to internalize a sufficient number of gold-silica
nanoshells to be useful for PPTT in in vitro systems consisting of cell monolayers or 3-D
multicellular spheroids (Baek et al., 2011; Trinidad et al., 2014).

1.4 Plasmonic Photothermal Therapy
The use of hyperthermia in the destruction of solid tumors has been under
investigation for some time. The efficacy of thermal therapy through a variety of heat
sources including laser light, focused ultrasound, and microwaves has been studied by
numerous investigators. Compared to normal tissue, tumors have a poor blood supply and,
therefore a reduced heat tolerance which makes them susceptible to hyperthermia
treatments. In addition, hyperthermia causes irreversible cell damage by loosening the
cell membrane and denaturing critical proteins. There are numerous benefits of thermal
therapy over conventional resection: most approaches are minimally or non-invasive,
relatively simple to perform, and have the potential of treating embedded tumors in vital
regions where surgical resection is not feasible. Ultimately, the difficulty of this type of
therapy is that the activating energy source must have significant penetration into tumor
tissues while, at the same time, sparing normal tissues. Simple heating techniques have
difficulties discriminating between tumors and surrounding healthy tissue, and often
result in the heating of intervening tissue between the source and the target site. Several
groups have investigated treatment of tumors through hyperthermia using deep
penetrating near infrared (NIR) lasers with or without contrast enhancing agents, however,
success with current systems has been modest (Chen et al., 1997; Prudhomme et al., 1996;
Chen et al., 1996).
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The emerging use of laser light to achieve controlled and confined thermal
damage to the tumor tissue has revolutionized cancer therapy. Lasers have been used in
medical applications since the 1960s, and the first reports of tumor eradication in 1965
sparked a wide interest in their use in oncologic applications. The laser light can either be
transmitted from an optical fiber tip to exposed tumors or be delivered into a confined
space via insertion of the fiber into the center of the target tumor, which is often called
interstitial laser hyperthermia (Bown 1983; Steger et al., 1989; Masters and Bown 1990;
Masters and Bown 1992a; Masters and Bown 1992b). Although reasonable tumor
selectivity can be achieved with interstitial laser hyperthermia, this is an invasive
technique. Light absorbing dyes have been used to increase tumor selectivity. Following
light excitation of the dye molecule, electrons transition from the ground state to the
excited state. Typically, the dye molecules relax via nonradiative decay channels
resulting in heating of the local environment around the light absorbing agents. If the
temperature increase is sufficient, the process leads to localized tissue destruction. The
photoabsorbing agents can be naturally occurring chromophores in the tissue or
externally added dye molecules such as indocyanine green, naphthalocyanines, and
porphyrins coordinated with transition metals (Huang et al., 2008). Unfortunately, natural
chromophores are characterized by very low absorption and therefore they are inefficient
hyperthermia agents. A potential solution to this problem is the laser activation of NIRabsorbing metallic nanoparticles, termed plasmonic photothermal therapy (PPTT)
(Anderson and Parrish 1983) (Fig 4).
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Figure 4 NIR light ablated PC3 prostate tumor cells with nanoshell treatment. In vitro cellular ablation with bare gold/
gold sulfide nanoparticles following incubation and laser application. Yellow circle indicates the laser spot; live/dead
stain for viability shows dead cell as red while viable cells appear green. White bars = 100 microns. (Gobin et al.,
2011).
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Figure 5 Gold nanoshell plasmon resonances for a 120 nm core with indicated shell thickness (Mody et al. 2010).

In recent years, the rapid development of nanotechnology has provided a variety
of nanostructures with unique optical properties that may prove useful in biology and
biomedical applications (El-Sayed, 2001; Katz and Willner 2004). From the cancer
therapy point of view, noble metal nanoparticles are very useful PPTT agents due to their
enhanced absorption cross sections, which are four to five orders of magnitude larger
than those offered by conventional photoabsorbing dyes which make them more effective
photothermal coupling agents (Huang et al., 2008). Nanoshells are a new class of
optically tunable nanoparticles composed of a dielectric core (silica) coated with an
ultrathin metallic layer of gold (Oldenburg et al,. 1999). Through adjusting the thickness
of the core and shell, nanoshells can be manipulated to absorb or scatter light at a desired
wavelength across visible and NIR wavelengths (Fig. 5). This optical tunability permits
the fabrication of nanoshells with a peak optical absorption in the NIR, a region of light
12

where optical penetration through tissue is optimal (Weissleder, 2001). In general, the
efficacy and stability of the metal shell on the nanoshell converts absorbed light to heat
with an efficiency that far exceeds that of conventional dyes. Furthermore, the absorption
properties of the nanoshells are dependent upon the material’s rigid metallic structure
rather than the more labile molecular orbital electronic transition of conventional dyes,
which in turn makes the nanoshells less susceptible to photobleaching. The efficacy of
nanoshells as a NIR absorber has already been demonstrated in a series of in vivo
magnetic resonance thermal imaging (MRTI) studies examining temperature profiles of
nanoshell-loaded tumors irradiated with NIR light. These studies found that nanoshells
absorbed NIR light and generated increased temperatures sufficient to produce
irreversible photothermal damage to subcutaneous tumors (Hirsch et al., 2003a).
To improve the biocompatibility of the nanoshells, ‘stealthing’ polymers like
poly(ethylene glycol) (PEG) can be crafted to nanoshell surfaces using simple molecular
self-assembly techniques (Hirsch et al., 2003b). It has been demonstrated that stealthing
liposomes as well as other biomolecules and materials with PEG suppresses
immunogenic responses, improving blood circulation times and overall material/implant
performance (Chen and Scott 2001; Harris et al., 2001).
In PPTT electromagnetic radiation (usually in the visible to near-infrared
wavelengths) incident on gold-based nanoparticles is converted to heat and, as such, this
technique can be used as a therapeutic approach to destroy cancer cells. The maximum
absorption wavelength depends on a number of factors including nanoparticle
composition, size and geometry. Ideally, nanoparticles should demonstrate significant
absorption in the near-infrared since this wavelength region has high penetration in
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biological tissues (Trinidad et al., 2014). This provides the rationale for using gold-silica
nanoshells with silica core diameters of 120 nm and gold shells of 15 nm thickness as
they have maximum light absorption around 800 nm. In addition to their favorable
absorption properties, 150 nm gold-silica nanoshells are also ideally suited for passive
delivery to tumors via the enhanced permeability and retention (EPR) effect
(Puvanakrishnan, 2012). Preferential accumulation of 20-300 nm particles in tumors
occurs due to the leaky tumor vasculature (enhanced permeability) and poor lymphatic
drainage (enhanced retention).
The efficacy of chemotherapeutic agents is sensitively dependent on the ability to
deliver these compounds in therapeutic concentrations to the tumor site. Most
chemotherapeutic agents demonstrate a high efﬁcacy with a variety of tumors.
Nevertheless, nonspeciﬁc delivery leads to signiﬁcant normal tissue toxicities and limits
dosages to levels far below those required to destroy most malignancies. To overcome
this problem, the combined treatment of chemotherapeutic agents with PPTT is proposed.
Heat treatment, called hyperthermia, has been demonstrated to augment the cytotoxicity
of some chemotherapeutic agents, resulting in similar cure rates and reduced morbidity
with lower drug doses (Hahn et al., 1975; Hildebrandt et al., 2002; Jones et al., 2005;
Tang and McGoron 2009).

1.5 Bleomycin
One of the anti-cancer agents under investigation for this research is a
chemotherapeutic compound called bleomycin (BLM) (Fig 6). Bleomycin is a 1.5 kDa
glycopeptide antibiotic produced from the bacterium Streptomyces verticillus. It was
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discovered by Umezawa et al. in 1966 and was found to be cytotoxic to eukaryotic cells
due to its ability to induce DNA breaks (Suzuki, 1970). Bleomycin is typically used for
the treatment of squamous cell carcinomas of the head and neck, esophagus, bronchus,
and skin, as well as testicular cancer and Hodgkin’s and non-Hodgkin's lymphoma (Mir
et al.,1996; Berg et al.,2005). Side effects include pneumonitis (in 46% of patients) and
lung fibrosis (in 3% of patients) which can occur after a cumulative dose of 300 mg m-2
(Mir et al., 1996). Patients are typically treated two to three times per week or given a
continuous low dose for several days. The drug has a biological half-life in blood of 2-4
hours after intravenous injection, with 70% excreted after the first 24 hours (Mir et al.,
1996 ).

Figure 6 Structure of bleomycin. (Barber et al. 1981)

Bleomycin has a large hydrophilic structure comprised of four major parts:
terminal amine, bithiazole, pseudopeptidic, and glycannic (Mir et al., 1996).
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The

terminal amine group interacts with nucleic acids, anchoring the bleomycin to the double
helix strand. The bithiazole domain serves to bind with DNA and interacts with the DNA
minor groove. The pseudopeptidic group is responsible for binding to transition metals
and functions as DNA sequence selectivity and strand cleavage. Last, the function of the
glycannic domain is still under investigation. Bleomycin forms metal oxide complexes by
both binding to oxygen as well as redox-active transition metal ions Fe2+, Co2+, Zn2+,
Ni2+, and Cu2+ (Suzuki, 1970). Bleomycin has been shown to amass in endocytic
vesicles and has limited ability to penetrate the cell membrane.

Hence, bleomycin

typically enters the cell through receptor-mediated endocytosis by binding to a 250 kDa
membrane receptor (Berg et al., 2005). Though bleomycin generally demonstrates some
potency once inside the cell, it still needs to diffuse through the nuclear membrane in
order to interact with the DNA.
The primary biochemical action of bleomycin is through induction of DNA strand
breaks, and some suggest bleomycin inhibits incorporation of thymidine into the DNA
strand (Van Meir et al., 2010). In vitro, bleomycin DNA cleavage depends on oxygen and
metal ions, but the exact mechanism of DNA strand scission is still unresolved. It has
been suggested that bleomycin chelates metal ions, primarily iron, producing a
pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals
which can cleave the DNA. An alternative hypothesis proposes that bleomycin may bind
at specific sites in the DNA strand and induce scission through abstracting the hydrogen
atom from the base, which would result in strand cleavage as the base undergoes a
Criegee-type rearrangement or forms an alkali-labile lesion (Quada et al., 1998). The
intracellular response to bleomycin damage is illustrated in Figure 7.
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Figure 7 Intracellular response network to bleomycin damage (Chen and Stubbe, 2005)

1.6 Doxorubicin
Doxorubicin is the trade name of the liposomal formulation Doxil, also known as
hydroxydaunorubicin (Fig. 8). It is an anthracycline antibiotic, closely related to the
natural product daunomycin. Like all anthracyclines, it works by intercalating DNA, with
the most serious adverse effect being life-threatening heart damage (Tacar et al., 2013). It
is commonly used in the treatment of a wide range of cancers, including hematological
17

malignancies, soft tissue sarcomas and many types of carcinomas, including those of the
breast (Tacar et al., 2013).

Figure 8 Structure of doxorubicin

Doxorubicin

interacts

with

DNA

by

intercalation

and

inhibition

of

macromolecular biosynthesis (Hahn et al., 1975). This inhibits the progression of the
enzyme topoisomerase II, which relaxes supercoils in DNA for transcription (Pigram et
al., 1972). Doxorubicin stabilizes the topoisomerase II after it has broken the DNA chain
for replication which prevents the DNA double helix from being resealed and therefore
stops the process of replication. The planar aromatic chromophore portion of the
molecule intercalates between two base pairs of the DNA, while the six-membered
daunosamine sugar sits in the minor groove and interacts with flanking base pairs
immediately adjacent to the intercalation site, as evidenced by several crystal structures
(Pang et al., 2013). By intercalation, doxorubicin can also induce histone eviction from
18

chromatin. As a result, DNA damage response, epigenome and transcriptome are
deregulated in doxorubicin-exposed cells (Tang and McGoron, 2009). A summary of the
action of doxorubicin is illustrated in Figure 9.

Figure 9 Action of doxorubicin in a stylized cancer cell. (Thorn et al. 2010)
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1.7 Cisplatin
Cisplatin is one of the most potent antitumor agents known, displaying clinical
activity against a wide variety of solid tumors. Cisplatin, cisplatinum, or cisdiamminedichloridoplatinum(II) (CDDP) is a member of a class of platinum-containing
anti-cancer drugs which now also includes carboplatin and oxaliplatin (Fig. 10). These
platinum complexes react in vivo, binding to and causing crosslinking of DNA, which
ultimately triggers apoptosis (programmed cell death) (Pruefer et al., 2008)

Figure 10 Structure of cisplatin

Cisplatin’s cytotoxic mode of action is mediated by its interaction with DNA to
form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal
transduction pathways, including those involving ATR, p53, p73, and MAPK, and
culminate in the activation of apoptosis (Fig. 11). DNA damage-mediated apoptotic
20

signals, however, can be attenuated, and the resistance that ensues is a major limitation of
cisplatin-based chemotherapy (Siddik. 2003). Cisplatin induces DNA crosslinks in
several different ways thereby interfering with cell division by mitosis. The damaged
DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair
proves impossible (Liu et al., 2008). Most notable among the changes in DNA are the
1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG)
adducts which form nearly 90% of the adducts and the less common 1,2-intrastrand
d(ApG) adducts (Matysiak et al., 2009). 1,3-intrastrand d(GpXpG) adducts occur but are
readily excised by nucleotide excision repair (NER). Other adducts include inter-strand
crosslinks and nonfunctional adducts that have been postulated to contribute to cisplatin's
activity (Matysiak et al., 2009). Interaction with cellular proteins, particularly HMG
domain proteins, has also been advanced as a mechanism of interfering with mitosis,
although this is probably not its primary method of action (Matysiak et al., 2009).
Cisplatin also activates human natural killer cells and monocytes and
upregulates interleukin-2-induced lymphokine activated killer cells (Sodhi et al.,
1992). It is thought that cisplatin-mediated cancer remission is a combined outcome
of its immunostimulating and cytotoxic effects. (Pai et al., 1997).
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Figure 11 Mechanisms involved in inhibiting the apoptotic signal in cisplatin-resistant tumor cell (Siddik. 2003)

1.8 Scope of Work
The purpose of this research is to investigate the combined effects of a number of
commonly used chemotherapeutic agents (bleomycin, doxorubicin, cisplatin) with goldsilica nanoshell- induced hyperthermia on a human head and neck cancer cell line. This
will be accomplished by comparing the toxicity of each treatment (chemotherapy or
22

photothermal therapy) with the combined treatment. In the proposed in vitro studies,
macrophages will be used as nanoshell delivery vehicles.
For comparative purposes, a separate set of experiments will be performed
employing a conventional hyperthermia technique in which the monolayers will be
exposed to elevated temperatures in an incubator. In all cases, a cell proliferation
colorimetric assay will be used to determine therapeutic efficacy.

Figure 12 Model of macrophage endocytosis of nanoparticles and incorporation into tumor spheroids followed by
laser-mediated thermal ablation (Makkouk and Madsen 2013)

Hypothesis: The combined macrophage-mediated chemo-thermal treatment will yield
greater cell toxicity than individual treatments consisting of either chemotherapy or
photothermal therapy. The increased cell toxicity will be similar to that observed in
monolayers subjected to combined chemotherapy and conventional hyperthermia.
There are two particularly novel aspects associated with the proposed work: (1) the
use of nanoshell PPTT-induced hyperthermia combined with chemotherapeutic
agents, and (2) macrophage-mediated delivery of nanoshells.
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CHAPTER 2

MATERIALS AND METHODS
2.1 Cell Lines
All experiments were performed in vitro utilizing a human hypopharyngeal
squamous cell carcinoma line (FaDu) and murine lymphocytic monocytes (P388D-1). All
work was done inside a Labconco Class II Biohazard Cabinet (Labconco Corp., Kansas
City, MO) at the University of Nevada, Las Vegas (UNLV) unless otherwise specified.
Cells were incubated at 37°C, 5.0% CO2, and 95% humidity inside a VWR incubator
(VWR International, LLC. West Chester, PA). The cell line was kept in Gibco
Dulbecco’s Modified Eagle medium (DMEM) (Invitrogen Corp., Carlsbad, CA) with
10% heat-inactivated fetal bovine serum (FBS), 25 mM HEPES buffer (pH 7.4), and
penicillin (100 U/ml). All monolayer cells were sub-cultured using the same technique.
After checking the confluence, the T-75 flask was emptied of all media and the
cells washed with 5 ml of Gibco phosphate buffered saline (PBS) with pH of 7.2
(Invitrogen Corp., Carlsbad, CA). Next, 5 mL of Gibco 0.25% Trypsin-EDTA
(Invitrogen Corp., Carlsbad, CA) was added and the flask slowly rocked approximately
twenty times. The trypsin was removed after 5 min. Trypsin is a proteolytic enzyme,
which functions to detach adherent cells from the flask surface. Following the 5 min.
trypsin incubation, 5 mL of DMEM was added to the flask and the suspended cell media
was pipetted up and down several times to ensure the separation of cells. Thereafter, 2
mL of the media was added to 13 mL of fresh DMEM inside a new T-75 flask. Two
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flasks were seeded in this fashion to ensure a consistent supply of cells for the
experiments.

2.2 Monolayer Plating
The monolayer plating consisted of a mixture of FaDu cells and P388D1 murine
monocytes loaded with gold nano-shells (AuroShell™), purchased from Nanospectra
Biosciences Inc. (Houston, TX). Gold nanoshells (4.3 x 109) were incubated with
monocytes (2.0 x 105 cells ml-1) under standard conditions for 24 h prior to the cell
plating. After 24 h of incubation, monocytes were treated with mitomycin C for one hour
to prevent cell division. Monocytes were washed twice with PBS in order to remove noningested nanoparticles and mitomycin C residues.
On the day of plating, FaDu cells (70% confluence) were harvested from the
growth flask and transferred to a 15 ml centrifuge tube with 11ml of DMEM with a cell
concentration of 20,000 FaDu cells ml-1 (Total of 2.2 x 105 cells). 1.1 x105 loaded
monocytes were added to the 15 ml centrifuge tube making the ratio of FaDu-to-murine
monocytes 2:1. The 15 ml centrifuge tube was slightly vortexed for 10 seconds to achieve
better mixing of the cells. The cell solution was then transferred to a 50 ml reservoir and
100 µl of the cell solution was placed in each well of a 96-well plate resulting 2,000
FaDu cells and 1,000 monocytes per well.
For the chemo agent toxicity plates and heat simulation experiment, each well in
the 96-well plate was filled with the cell solution except the 12th column which was left
empty.
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2.3 Cell Proliferation Assay (MTS)
The CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega,
Madison, WI) is a colorimetric method for determining the number of viable cells in
proliferation or cytotoxicity assays. The CellTiter 96® AQueous One Solution Reagent
contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], inner salt, MTS, and an
electron coupling reagent (phenazine ethosulfate; PES). PES has enhanced chemical
stability, which allows it to be combined with MTS to form a stable solution. The MTS
tetrazolium compound is bioreduced by cells into a colored formazan product that is
soluble in tissue culture medium (Figure 13). This conversion is presumably
accomplished by NADPH or NADH produced by dehydrogenase enzymes in
metabolically active cells. The quantity of formazan product, as measured by absorbance
at 490 nm, is directly proportional to the number of living cells in culture. The
absorbance at 490 nm in each well is measured using a microplate reader.

Figure 13 Chemical Structure of MTS to Formazan
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For every measured 96 well plate, 30µl of MTS reagent was added into each well
containing cells. 150 µl DMEM and 30µl of MTS reagent were added into each well of
the 12th column of each plate. This last column contained no cells and thus provided a
measure of the background noise of the MTS assay. The plates were incubated in the
VWR incubator for one hour. After incubation, the plates were transferred to an Infinite®
M1000 PRO microplate reader (TECAN Group Ltd., Männedorf, Germany) for
absorbance reading at 490 nm. The results were recorded on Microsoft Excel worksheets.

2.4 Drug Toxicity
The FaDu cell/nanoshell-loaded P388D1 murine monocyte suspension was
injected into each well of a 96-well plate (except the 12th column). A total of three well
plates were prepared (one for each chemotherapeutic drug). Drugs were added to DMEM
medium to obtain concentrations of: 0.1-10 µg ml-1 (bleomycin), 0.001-0.05 µg ml-1
(doxorubicin) and 1-75 µg ml-1 (cisplatin). The drugs were added to each well in 7 of the
11 columns containing the cell/loaded monocyte suspension 24 h after the initial cell
seeding. Two non-drug columns served as positive and negative controls, respectively
while two columns containing cell mixtures were unused. Typically, each column (eight
wells) on a plate contained one drug concentration. In all cases, suspensions and
chemotherapeutic agents were incubated for five days in an incubator (VWR
International, LLC. West Chester, PA). Following incubation, 0.1 ml of 90% ethanol was
added to each well of one of the non-drug columns (eight wells total) of each of the three
plates. These columns served as positive controls since ethanol is toxic to cell
suspensions. Any signal emanating from these wells was considered background noise,
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i.e., a reference point for total cell death. Following the 15 min. ethanol incubation, MTS
assays were performed to determine viability. The MTS reagent (30 µl) was added to
each well and after 60 min incubation, the plate was placed in a microplate reader
(Infinite® M1000 PRO) and the fluorescence emission from each well was recorded. The
background signal (MTS column #12) and the ethanol treated column was subtracted
from each well and the resultant signal was normalized to the signal from the negative
control group, i.e., the column containing no drugs (cell suspensions only). The
pharmacological potency resulting in approximately 60-90% survival was used in
subsequent combined therapy studies.

2.5 Photothermal Toxicity
A fiber-coupled diode laser (Intense, North Brunswick, NJ) was used to irradiate
cells at a wavelength of 805 nm. Each well was irradiated separately using an irradiance
of 7 W cm-2. Three irradiation times were investigated: 5, 7.5 and 10 min corresponding
to radiant exposures of 2.10, 3.15 and 4.20 kJ cm-2. The radiant exposure resulting in
approximately 90% survival was used in subsequent combined therapy studies. All
irradiations were performed in a specially designed incubator in order to maintain
physiological conditions, in which the incubator was kept at a constant temperature of 37
o

C and acetic acid was added to sodium bicarbonate for CO2 production. The 600 µm dia.

optical fiber (Model FD1; Medlight, Ecublens, Switzerland) connected to the diode laser
was inserted through an opening at the top of the incubator and cells in individual wells
of the 96-well plate were irradiated by placing the fiber in contact with the bottom of the
plate (irradiation beam diameter = 8 mm). Only every third column and every third row
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of the well plate contained cells resulting in a total of 12 wells per plate and a total of two
plates for this experiment. The empty wells provided a barrier preventing scattered light
from irradiating cells in adjacent wells. As previously described, the 12th column
contained MTS reagent and no cells and one column with cells served as positive control.
After the irradiation, the plates were incubated in the VWR incubator for 5 d. Following
incubation, MTS assays were performed as previously described. The background signal
from the MTS-only column and the ethanol treated column was subtracted from the
treatment columns and results are normalize to the no PPTT treatment control group.

2.6 Combined Chemo- and Photothermal Treatment
Based on the toxicity results for each of the three drugs, concentrations resulting
in 70-90 % survival were chosen, i.e., 5 µg ml-1 bleomycin, 10 µg ml-1 cisplatin, and
0.005 µg ml-1 doxorubicin were added to the combined FaDu cells and P388D1 murine
monocytes monolayer in the 96 well plates prior to the irradiation; Only every third
column of the well plate contained cells, resulting in a total of 6 wells per treatment
group and 12 wells per plate. The empty wells provided a barrier preventing scattered
light from irradiating cells in adjacent wells. The control groups were established with the
same concentrations of chemo agents as in the corresponding combined PPTT and chemo
treatment groups in one 96 well plate (eight well total for each group) and were
maintained in the VWR incubator for the duration of the trial. Each photothermal treated
well was irradiated separately using an irradiance of 7 W cm-2 (8 mm beam diameter) for
7.5 minutes resulting in a radiant exposure of 3.15 kJ cm-2. Otherwise, the irradiation
protocol using the 805 nm fiber-coupled diode laser was identical to that previously
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described in section 2.5. Following treatment, the plates were incubated for 5 d and MTS
assays were performed at the end. The background signal from the MTS-only column and
the ethanol treated column was subtracted from the treatment columns, and results were
normalized to the no treatment control group.

2.7 Conventional Hyperthermia
Bleomycin (5 µg ml-1), cisplatin (10 µg ml-1), and doxorubicin (0.005 µg ml-1)
were added to the combined FaDu cells and P388D1 murine monocytes monolayer in
three 96 well plates (total of eight wells per drug in each plate) prior to the hyperthermia
treatments. As previously described, the interval between cell seeding and addition of
drugs was 24 h. Immediately thereafter, each 96-well plate was placed in the specially
designed irradiation incubator for 45 min. at one of three temperatures: 37, 41 or 44 oC.
During the 45 min. treatment, aceticylic acid was added to sodium bicarbonate for CO2
production. Following treatment, each plate was transferred to the main incubator After 5
d of incubation, the MTS assay was performed. The background signal from the MTSonly column and the ethanol treated column was subtracted from the treatment columns
and results were normalized to the 37 oC no-drug control group.

2.10 Statistical Analysis
Data analysis was performed in Microsoft Excel. All data were normalized to the
control group of each individual experiment and all error bars represent standard
deviations. In order to determine the degree of interaction between PPTT and the chemo-
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agents the following equation was used (Drewinko et al. 1976 – not found in reference
section – please add):
𝑆𝐹 𝑃𝑃𝑇𝑇 𝑥 𝑆𝐹 𝐶ℎ𝑒𝑚𝑜
𝛼=
(Eq. 1)
𝑆𝐹𝑃𝑃𝑇𝑇+𝐶ℎ𝑒𝑚𝑜
The numerator includes the product of the surviving fraction (SF) of the individual
treatments separately and the denominator includes the surviving fraction of the
combined treatments. A value of α=1 indicates an additive effect. A value of α < 1 or α >
indicates an antagonistic or synergistic effect, respectively.
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CHAPTER 3

RESUTLS
3.1 Drug Toxicity
In order to determine the optimal drug levels for evaluating the effects of
combined chemotherapy and PPTT, titrations were performed for each drug. The results
are shown in Figures 14 – 16 for each respective chemotherapeutic agent. In all cases, the
surviving fraction was normalized to the negative (no drug) controls. As expected, the
results show a decrease in survival with increasing drug concentrations. As illustrated in
Figure 14, the 50% survival dose (LD50) for doxorubicin in this cell mixture is
approximately 0.0075 µg ml-1. All cells were killed at a concentration of 0.05 µg ml-1.
The bleomycin titration results (Figure 15) show that the LD50 is approximately 5
µg ml-1 which is lower than the corresponding value for cisplatin (Figure 16).
Collectively, the data show that, for this particular cell line, doxorubicin has the highest
toxicity while cisplatin is the least toxic. Based on the previously established criterion of
60-90% survival, the results in Figures 14-16 suggest that doxorubicin, bleomycin and
cisplatin, concentrations of 0.005, 5, and 10 µg ml-1, respectively should be used in the
combined treatments.
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Figure 14 Doxorubicin toxicity titration from 0.001 to 0.05 ug ml-1. Each data point represents mean ± standard
deviation.

Figure 15 Bleomycin toxicity from 0.1 to 10 ug ml-1 Each data point represents mean ± standard deviation.
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Figure 16 Cisplatin Toxicity titration from 1 to 75 ug ml-1 Each data point represents mean ± standard deviation.

3.2 Photothermal Toxicity
As illustrated in Figure 17, a 7 W cm-2 irradiance had little effect on overall
survival for the treatment times investigated: irradiation times of 7.5 and 10 min. resulted
in only 15% cell kill. Based on these results, an irradiation time of 7.5 min. was chosen
for the combined PPTT and chemotherapy studies.
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Figure 17 Photothermal therapy potency using fiber-coupled diode laser at 810 nm. Each data point represents mean ±
standard deviation.

3.3 Combined Chemo- and Photothermal Treatment
As illustrated in Figure 18, surviving fractions for bleomycin, cisplatin, and
doxorubicin were 68.2 ± 5.7 %, 68.1 ± 4.43% and 81.8 ± 3.9 % respectively. The
toxicity of photothermal therapy was 79.4 ± 11.2 %. Surviving fractions for combined
photothermal and chemo treatments were 65.08 ± 10.2 %, 49.2 ± 5.1 %, and 30.9 ± 5.8
% for doxorubicin, bleomycin and cisplatin, respectively. The corresponding alpha values,
calculated from equation 1 are shown in Table 2. The alpha values suggest slight additive
effects for the PTT + doxorubicin and PTT + bleomycin combinations, while a
synergistic effect was noted for the PTT + cisplatin treatment.
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Figure 18 Combined chemo and photothermal treatment. Surviving fraction was normalized to the positive (no
treatment) controls. Each data point corresponds to the mean and standard error of three trials.

Trial Group
PPTT + doxorubicin 0.005 µg ml-1
PPTT + bleomycin 5 µg ml-1
PPTT + cisplatin 10 µg mL-1

α
0.83±0.19
1.09±0.20
2.10±0.50

Table 2 Alpha values of combined chemo and photothermal treatments

3.4 Conventional Hyperthermia
As shown in Figure 19, surviving fractions for doxorubicin, bleomycin, and
cisplatin at 37 ̊ C were 87.7 ± 4.1 %, 78.2 ± 3.5% , and 66.9 ± 5.4 % respectively.
Surviving fractions for cells exposed to 41 and 44 oC were 88.0 ± 5.2 % and 95.4 ± 2.4%,
respectively. Surviving fractions for combined 41 oC hyperthermia and chemo treatments
were 86.2 ± 2.6 %, 81.4 ± 3.4 % , and 67.6 ± 7.6 % for doxorubicin, bleomycin and
cisplatin, respectively. The corresponding values for combined treatments at the higher
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temperature (44 oC) were 65.4 ± 3.0 %, 51.0± 4.2 % , and 37.3 ± 8.8 %. The
corresponding alpha values calculated from equation 1 are shown in Table 3. Alpha
values for the combined treatments at the lower temperature (41 oC) suggest a slight
additive effect while, at the higher temperature, a small degree of synergism is observed
for each drug.

Figure 19 Combined hyperthermia and chemotherapy treatments for three different drugs. Survival fraction was
normalized to the positive (no treatment) controls. Each data point represents mean ± standard deviation.

Trial Group (41 ̊C)
Heat + doxorubicin 0.005 µg
ml-1
Heat + bleomycin 5 µg ml-1
Heat + cisplatin 10 µg mL-1

α
Trial Group (44 ̊C)
α
-1
0.89±0.07 Heat+Doxorubicin 0.005 µg ml 1.28±0.11
0.85±0.07 Heat + bleomycin 5 µg ml-1
0.87±0.13 Heat + Cisplatin 10 µg ml-1

Table 3 Alpha values of combined hyperthermia and chemo treatments
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1.46±0.16
1.71±0.43

CHAPTER 4

DISCUSSION
Current treatment for many cancers such as brain, hypopharyngeal squamous cell
carcinomas and breast cancers include surgical resection of the tumor followed by
various concurrent or subsequent treatments such as chemo and/or radiotherapy. The goal
of subsequent treatments is to eliminate the malignant cells residing in the margin
surrounding the resection cavity thereby reducing or eliminating recurrence.
Unfortunately, in many cases, none of the standard treatment regimens have proven to be
successful suggesting that alternative therapeutic approaches are required. This research
investigated the utility of combining traditional chemotherapy agents with nanoshell
mediated laser-induced hyperthermia in an in vitro system consisting of murine
monocytes and human hypopharyngeal cancer cells.
Chemotherapy is one of the standard treatment options for cancer patients. The
efficacy of chemotherapeutic agents is sensitively dependent on the ability to deliver
these compounds in therapeutic concentrations to the tumor site. Most chemotherapeutic
agents demonstrate a high efﬁcacy with a variety of tumors. Nevertheless, nonspeciﬁc
delivery leads to signiﬁcant normal tissue toxicities and limits dosages to levels far below
those required to destroy most malignancies. Heat treatment, called hyperthermia, has
been demonstrated to augment the cytotoxicity of some chemotherapeutic agents,
resulting in similar cure rates and reduced morbidity with lower drug doses (Hahn et al.,
1975; Hildebrandt et al., 2002; Jones et al., 2005; Tang and McGoron, 2009)
Hyperthermia treatments have been under clinical investigation for some time.
Compared to normal tissues, tumors are more susceptible to hyperthermia because of
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their poor blood supply and subsequent reduced heat tolerance. Furthermore, heat
modifies the cytotoxicity of many chemotherapeutic agents. The extent of ‘thermal
chemosensitisation’ both in vitro and in vivo can be quantified by comparing tumors
treated with drug alone and those treated with a combination of drug and hyperthermia.
Several studies have shown S-phase specific cell lethality of cells exposed to a variety of
chemotherapeutic agents (Grisham et al., 1980). Observations suggest that moderate heat
treatment itself does not induce chromosomal DNA strand breaks directly, but can alter
chromatin structure influencing DNA repair (Kampinga and Dikomey, 2001). In addition,
heat treatment induces both apoptosis and necrosis, and the form of death changes from
apoptosis to necrosis above a certain threshold temperature (Harmon et al., 1990).
To overcome the non-specific targeting of chemotherapy, the combined treatment
of chemotherapeutic agents with PPTT is proposed. This is the first study to investigate
the efficacy of combined chemotherapy and PPTT using monocytes as delivery vehicles
for gold nanoshells.
The effects of bleomycin, cisplatin and doxorubicin have been investigated in a
wide variety of cancer cell lines. For example the LD50 for bleomycin in a F98 rat glioma
cell line ranged from 0.5 to 0.75 µg ml-1 (Mathews et al., 2012; Madsen et al., 2009)
while the corresponding values in human breast carcinomas was between 0.75 and 1.75
µg ml-1 (Mathews et al., 2012). These values are significantly lower than the LD50
observed for bleomycin in the present study employing the FaDu cell line (5 µg ml-1).
The LD50 for cisplatin in three human breast cancer cell lines (MCF-7, MDA-MB-435
and MDA-MB-231) was approximately 93 µg ml-1 while for doxorubicin it was 10 – 20
µg ml-1 in the MCF-7 cell line and 0.5 – 0.75 µg ml-1 in the MDA-MB-435 and MDA-
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MB-231 breast cancer lines (Mathews et al., 2012). In comparison, the LD50 in FaDu
cells was approximately 15 and 0.0075 µg ml-1 for cisplatin and doxorubicin, respectively.
Differences in LD50 values between the present work and the results of Mathews et al.
(2012) are likely due to the different cell lines investigated. The observation that different
cell lines have wide varying sensitivities to chemotherapeutic agents is illustrated in the
doxorubicin data of Mathews et al. (2012) which show that, even for the same type of
cancer (breast), there can be a significant variation in sensitivities to chemotherapeutic
drugs. Other reasons for the observed differences between the present study and those of
others include differences in: (1) survival assays (MTS vs. clonogenic survival) and (2)
growth conditions.
In all cases, low drug concentrations resulted in survival fractions exceeding
100%. This was likely due to a phenomenon known as hypergenesis in which cancer cells
are stimulated to divide in response to external stimuli.
PPTT has been shown to be very effective for inducing rapid temperature
elevations in tumors containing NIR absorbing gold nanoshells while minimizing damage
to surrounding normal tissues. Since squamous cell carcinomas of the head and neck
contain significant concentrations of macrophages, these tumors are ideally suited for
macrophage-mediated therapies (Trinidad et al., 2014). Both stromal and tumor cells
produce a wide variety of chemokines and growth factors which have the ability to recruit
circulating monocytes and differentiate them into macrophages (Lewis and Pollard, 2006;
Galdiero et al., 2013). The tendency of macrophages to migrate and accumulate in tumors,
especially hypoxic regions, makes them attractive delivery vectors for both therapeutic
and diagnostic agents including nanoparticles.
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PPTT-induced cytotoxic effects depend on the total light energy (radiant exposure)
delivered. Therefore, higher incident laser powers (irradiances) allow for shorter
treatment times. For example, doubling the irradiance reduces the treatment time by onehalf. Effective PPTT requires temperatures in the range of 46 to 60 oC, however, higher
temperatures may be required in hypoxic, low pH environments found in many tumors
(Huang et al., 2008.). PPTT efficacy is dependent on a number of factors, including light
distributions in tissues. Due to the limited penetration depth of 810 nm light in brain
tissues (0.5 – 1.0 cm; Madsen and Wilson 2012), PPTT may require direct light delivery
via optical fibers. In addition to the light distribution, the concentration of nanoparticles
in the tumor tissue is also important and should be optimized to produce sufficient
temperature elevations for efficient PPTT (Trinidad et al., 2012). Since PPTT is oxygenindependent, it’s ideally suited for the treatment of tumors with high fractions of hypoxic
cells.
A number of studies have demonstrated the efficacy of PPTT using gold
nanoshell loaded macrophages or monocytes in in vitro systems consisting of human
glioma spheroids (Baek et al., 2011; Chhetri et al. 2014.) and human head and neck
squamous carcinoma cell lines (Trinidad et al. 2014). The results of Trinidad et al. (2014)
are particularly relevant to the present work since the same cell line (FaDu) was used.
The irradiation parameters (7 W cm-2; 5 – 10 min. exposures) and FaDu to monocyte
ratio (2:1) used in the present study were chosen based on the results of Trinidad et al
(2014) who showed that an irradiance of 7 W cm-2 for 5 min. (radiant exposure of 2.1 kJ
cm-2) resulted in approximately 95% survival in a 2:1 mixture of FaDu cells and
nanoshell-loaded macrophages. This is in excellent agreement with the results presented
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in Figure 17. Trinidad et al. (2014) found that significant cytotoxicity (20% survival)
required irradiances of 28 W cm-2 delivered over 5 min. (radiant exposure of 8.4 kJ cm-2)
These investigators also observed no cytotoxicity in empty macrophages exposed to 8.4
kJ cm-2. A similar finding was noted by Chhetri et al. (2014) who found no growth
inhibition in human glioma spheroids subjected to identical radiant exposures.
Collectively, these results suggest that a radiant exposure of 8.4 kJ cm-2 is insufficient to
produce hyperthermic effects in cells devoid of nanoshells. Based on these results, a
laser-irradiated only control group of FaDu cells was deemed unnecessary.
The results in Figure 17 show that PPTT is a very inefficient treatment modality.
For example, a radiant exposure of 4.2 kJ cm-2 produced only 15% cell kill. In
comparison, a radiant exposure of 0.75 J cm-2 used in photodynamic therapy, resulted in
50% survival of FaDu cells (Trinidad et al., 2014). As previously discussed, the
advantage of PPTT is that, unlike photodynamic therapy, it is an oxygen-independent
treatment modality and, as such, it is useful for the treatment of hypoxic cells.
In order to investigate the degree of interaction between the chemotherapeutic
agents and PPTT, suboptimal levels of both modalities were determined. The results
(Figure 18 and Table 2) show an additive effect (α ≈ 1) with concurrent treatments of
both PPTT and bleomycin and PPTT and doxorubicin. A synergistic effect (α > 1) was
noted for concurrent PPTT and cisplatin. The mechanism of synergism is not known, but
it likely has several components. Most importantly, all three drugs are incorporated into
DNA causing damage which often results in cell death unless the damage is repaired.
Since hyperthermia inhibits DNA repair, it’s postulated that the addition of heat enhances
the cytotoxicity of the chemotherapeutic agents via inhibition of DNA repair.
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PPTT-induced hyperthermia was compared with conventional incubator-induced
hyperthermia. The conventional hyperthermia data (Figure 19, Table 3) show that the
degree of interaction between the two modalities was sensitively dependent on
temperature: at 41 oC, all interactions were additive (or mildly antagonistic), while at 44
o

C all interactions were weakly synergistic. These results are in qualitative agreement

with studies showing additive effects for doxorubicin and synergistic effects for
bleomycin and cisplatin at 43.5 oC (Issels, 2008). The reason for the differences in alpha
values between the PPTT and conventional hyperthermia data is not known, but it’s
likely due to a temperature threshold effect. As illustrated in Table 3, synergistic effects
are more likely at higher temperatures. Since temperatures were not recorded during the
PPTT treatments, it’s possible that the laser irradiation parameters chosen were
insufficient to induce the threshold temperatures required for synergism with bleomycin
and doxorubicin.
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CHAPTER 5

CONCLUSIONS
The overall objective of the work was to investigate the effects of combined
PPTT and chemo agents on monolayers of FaDu hypopharyngeal squamous cell
carcinoma. Suboptimal levels of both drugs and PPTT were determined. The results
showed that PPTT combined with cisplatin resulted in some degree of synergism while
additive effects were observed for concurrent treatments of PPTT and doxorubicin and
PPTT and bleomycin. Concurrent treatments of conventional hyperthermia and
chemotherapeutic drugs demonstrated that the degree of interaction between the two
modalities was sensitively dependent on temperature: only additive (or mildly
antagonistic) interactions were observed at 41 oC while weakly synergistic interactions
were observed in all three cases at the higher temperature (44 oC). Compared to the
standard hyperthermia data, the lack of synergism between PPTT and bleomycin and
PPTT and doxorubicin might be due to an inability to attain the required temperature
threshold with the chosen laser irradiation parameters. In future experiments, this
discrepancy might be resolved by careful monitoring of temperatures during PPTT.
Although mechanistic studies were not performed, the likely explanation for the
observed synergism is the ability of hyperthermia to inactivate DNA repair mechanisms
thus resulting in increased cell death. This could be investigated in future studies using
chemotherapeutic agents that do not interact directly with DNA. Performing these
experiments in other cell lines may also shed some light on the mechanisms of action.
Finally, in vivo studies should be performed to evaluate the effectiveness of the combined
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treatments. This is important since vascular effects will most certainly play a major role
in the tumor’s response to these treatments.
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